Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY - touchPODCAST | Transcription & Insights

Audio

Description

touchPANEL DISCUSSION for touchRESPIRATORY Listen to leading experts discuss the serious consequences of severe type 2 asthma, how endotyping and biomarkers can help guide treatment selection in such patients, and how recent data and clinical guidelines can inform the long-term management of patients with severe type 2 asthma. The experts Dr Katharine Woessner, Scripps Clinic Medical Group, San Diego, CA, USA Prof. Louis-Philippe Boulet, Laval University, Quebec City, Canada Prof. Arnaud Bourdin, Arnaud de Villeneuve Hospital, Montpellier, France This touchPODCAST is for HCPs only. This activity is funded by an unrestricted independent educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme. This activity is jointly provided by USF Health and touchIME. For further information visit our website: https://touchrespiratoryime.org/endotypes-for-treatment-selection-in-severe-T2-asthma/

Transcription

This episode hasn't been transcribed yet

Help us prioritize this episode for transcription by upvoting it.

0 upvotes

🗳️ Sign in to Upvote

Popular episodes get transcribed faster

touchPODCAST

Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY

This episode hasn't been transcribed yet

Other recent transcribed episodes

13:00H | 21 DIC 2025 | Fin de Semana

10:00H | 21 DIC 2025 | Fin de Semana

12:00H | 20 DIC 2025 | Fin de Semana

2ª PARTE | 06 ENE 2026 | EL PARTIDAZO DE COPE

3ª PARTE | 22 ENE 2026 | EL PARTIDAZO DE COPE

3ª PARTE | 04 MAR 2026 | EL PARTIDAZO DE COPE

Sign in to Audioscrape

Share this moment